The Redwood City, Calif.-based company said it enrolled the 1st U.S. patient in the study, which looks to enroll a total of 120 patients undergoing lung resections which require surgical stapling.
The study will examine the effectiveness of the MicroCutter 5/80 surgical stapler at stopping the flow of blood, or hemostasis, the company said. The registry also aims to evaluate procedure-enabling aspects of the device in lobectomy or segmentectomy lung surgery procedures using minimally invasive techniques, including video assisted thoracic surgeries, robotic surgeries and open surgeries.
“We are proud to be working with these surgical pioneers at leading institutions to gather important clinical data on the MicroCutter 5/80 and its utility in thoracic surgery procedures,” CEO Julian Nikolchev said in a press release.
Participating in the study are Rochester, Minn.’s Mayo Clinic, the University of Alabama at Birmingham, University of Texas MD Anderson Cancer Center, the U.K.’s James Cook University Hospital and Scotland’s Royal Infirmary in Edinburgh.
“The Match registry will provide important clinical data regarding the hemostasis performance of the MicroCutter 5/80 while capturing video evidence of the ability of the device to navigate in tight spaces to enable less-invasive methods for treating patients undergoing lung surgery,” David Rice of Houston’s University of Texas MD Anderson Cancer Center said in prepared remarks.
Intuitive Surgical said the new development follows completion of a 6-month feasibility evaluation of Dextera’s MicroCutter as part of an ongoing deal between the companies.
Through the deal, Intuitive Surgical will take charge of development work for the robotic-compatible stapler system, while Dextera Surgical will focus on developing the stapler cartridge for the device.